Core Viewpoint - The company, Weikang Pharmaceutical, is expected to report a significant net loss for 2025, with projections indicating a loss between 245 million yuan and 170 million yuan, representing a year-on-year decline of 66.18% to 15.31% [1] Financial Performance - The company has experienced continuous losses for two consecutive years, with a net profit of -8.954 million yuan in 2023 and -147 million yuan in 2024 [1] - For the first three quarters of 2025, the company reported revenue of 151 million yuan, a year-on-year decrease of 59.20%, and a net profit of -124 million yuan [1] Stock Performance - The stock price has shown significant volatility, with a fluctuation range of 11.77% from February 5 to February 11, 2026, and a closing price of 28.35 yuan on February 11, reflecting a single-day increase of 2.75% [2] - The stock's trading volume indicates a net inflow of 7.4016 million yuan from major funds on February 11, with a noticeable cumulative net inflow over the past five days [2] - Technical indicators show the stock price is between the 20-day Bollinger Bands resistance level of 34.76 yuan and support level of 24.17 yuan, with the MACD indicator remaining negative but the short-term KDJ indicator rising to a neutral zone [2] Recent Events - On February 5, 2026, the company appointed a new board secretary, Wang Si, who is a "post-90s" internal promotion with no prior experience as a listed company secretary [3] - The company received a drug registration certificate from the National Medical Products Administration for its product, Er Dong Tang Granules, which is expected to enhance its product line, although the commercial impact remains to be seen [3]
维康药业2025年业绩预亏，股价波动明显